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Objective: Farnesoid X receptor (FXR) plays a prominent role in hepatic lipid metabolism. The FXR gene encodes four proteins with structural
differences suggestive of discrete biological functions about which little is known.
Methods: We expressed each FXR variant in primary hepatocytes and evaluated global gene expression, lipid proﬁle, and metabolic ﬂuxes. Gene
delivery of FXR variants to Fxr/ mouse liver was performed to evaluate their role in vivo. The effects of fasting and physical exercise on hepatic
Fxr splicing were determined.
Results: We show that FXR splice isoforms regulate largely different gene sets and have speciﬁc effects on hepatic metabolism. FXRa2 (but not
a1) activates a broad transcriptional program in hepatocytes conducive to lipolysis, fatty acid oxidation, and ketogenesis. Consequently, FXRa2
decreases cellular lipid accumulation and improves cellular insulin signaling to AKT. FXRa2 expression in Fxr/ mouse liver activates a similar
gene program and robustly decreases hepatic triglyceride levels. On the other hand, FXRa1 reduces hepatic triglyceride content to a lesser extent
and does so through regulation of lipogenic gene expression. Bioenergetic cues, such as fasting and exercise, dynamically regulate Fxr splicing in
mouse liver to increase Fxra2 expression.
Conclusions: Our results show that the main FXR variants in human liver (a1 and a2) reduce hepatic lipid accumulation through distinct
mechanisms and to different degrees. Taking this novel mechanism into account could greatly improve the pharmacological targeting and
therapeutic efﬁcacy of FXR agonists.
 2015 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Keywords FXR isoforms; Splicing; NAFLD; Insulin resistance; Energy metabolism1. INTRODUCTION
The regulation of hepatic energy storage and metabolism is essential
for an appropriate adaptation to ﬂuctuating metabolic demands.
Impaired control over hepatic lipid homeostasis can lead to excessive
lipid accumulation, a prominent feature of non-alcoholic fatty liver
disease (NAFLD), the most prevalent liver disease in Western societies
[1]. NAFLD is considered the hepatic hallmark of the metabolic syn-
drome and is strongly associated with hepatic insulin resistance and
type 2 diabetes. Farnesoid X receptor (FXR) is a bile acid-activated
nuclear receptor abundantly expressed in liver [2,3]. FXR expression
is markedly decreased in obese rodents and NAFLD patients [4e6].
Genetic FXR ablation promotes hepatic steatosis and hyperlipidemia
[7,8], whereas hepatic FXR expression and activation decrease local1Department of Physiology and Pharmacology, Molecular & Cellular Exercise Physiolog
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meostasis [9,10].
Four biologically active variants are expressed from the FXR gene
(FXRa1 through 4), resulting from alternative promoter usage and
mRNA splicing (Figure 1A) [11,12]. FXR isoforms display distinct
developmental and tissue-speciﬁc expression patterns and are
differentially regulated by metabolic cues [11,13,14]. FXRa3 and a4
possess extended N-termini with an A/B domain different from the one
in FXRa1 and a2. In addition, FXRa1 and a3 have a four amino acid
insert (MYTG) in the hinge region. The structural disparity between FXR
variants has functional implications that may inﬂuence the therapeutic
outcome of pan-FXR agonists. Indeed, FXR agonists promote distinct
gene expression proﬁles in hepatocytes, although the contribution of
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Figure 1: FXR isoform-speciﬁc gene regulation. (A) Human FXR isoforms. The different N-termini (orange in FXRa1/a2; pink in FXRa3/a4) and the MYTG insert in FXRa1/a3
are indicated. DBD, DNA-binding domain; LBD, ligand-binding domain. (BeC) FXR mRNA (B) and protein (C) levels in hepatocytes expressing each FXR variant or GFP alone
(control). (D) Gene expression analysis by qRT-PCR. (E) Heatmap of gene expression proﬁles in hepatocytes expressing each FXR isoform or GFP (F) Bioinformatic pathway analysis
of gene expression proﬁling. Represented are biological functions signiﬁcantly associated with one or more FXR isoforms. (G) Predicted effects on hepatic metabolism for each FXR
isoform. Z-score values indicate induction (orange) or repression (blue). Bars depict mean values and error bars represent SEM (n  3). *p < 0.05 vs. control. Up < 0.05 vs.
FXRa1/a2. xp < 0.05 vs. FXRa1/a3.
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in the A/B domain of FXR isoforms modulate coactivator interaction
[16], whereas the MYTG insert affects DNA-binding and target gene
speciﬁcity [11,14,17,18]. For example, the human bile salt export
pump (BSEP) is regulated by FXRs in an isoform-dependent manner,
predominantly by FXRa2 [14,18]. Notably, hepatic FXRa2/a1 ratios
and BSEP levels are decreased in hepatocellular carcinoma patients
and by pro-inﬂammatory stimulation [14]. To date, the regulation of
FXR splicing and its implications on hepatic energy metabolism remain
unknown.
Here, we show that FXR variants regulate hepatic lipid metabolism in an
isoform-dependentmanner. This constitutes a novelmechanismbywhich
alternative FXR splicing in the liver integrates systemic energetic demands
with a gene program of enhanced lipid handling/utilization and ketogen-
esis that positively impacts hepatic steatosis and insulin sensitivity.
2. MATERIALS AND METHODS
2.1. Generation of recombinant adenoviruses
Human FXRa1, a2, a3, and a4 were ampliﬁed by PCR and cloned into
the NotI/XhoI sites of a pcDNA3.1 plasmid (Life Technologies) con-
taining a FLAG tag between the BamHI and NotI sites. The cDNAs
encoding each FLAG-tagged FXR were subcloned into the pAdTrack-
CMV vector (Stratagene). Adenoviruses expressing each FXR variant
were generated using the AdEasy adenoviral vector system (Stra-
tagene), ampliﬁed in Ad-293 cells and puriﬁed by CsCl gradient
centrifugation as previously described [19]. All adenoviruses generated
also express GFP from an independent CMV promoter. An adenovirus
expressing only GFP was used as a control in all experiments.
2.2. Cell culture, transduction, and treatments
Primary hepatocytes from male C57BL/6J mice were isolated, cultured
and transduced as previously described [20]. Unless otherwise stated,
cells were processed for downstream analysis 36 h post-transduction.
For insulin treatment, cells were incubated in 5 mM glucose DMEM for
2 h prior to stimulation with 80 nM insulin for 20 min. For agonist
treatments, hepatocytes were treated with 250 mM CA for 24 h
following an 8e10 h transduction.
2.3. Gene expression analysis
Total RNA was isolated from frozen tissues or cultured cells, DNase-
treated, and reverse transcribed. Gene expression was analyzed us-
ing Applied Biosystems’ Power SYBR Green PCR Master Mix and ViiA 7
Real-Time PCR System. Gene expression was normalized to hypo-
xanthine phosphoribosyltransferase 1 (Hprt) expression and expressed
relative to experimental controls. Primer sequences are listed in
Table S1. Microarray analysis was performed using Affymetrix Mouse
Gene 1.1 ST Array and subsequent data analysis was conducted using
Qlucore Omics Explorer, Partek Genomics and Ingenuity Pathway
Analysis software suites. Affymetrix gene expression proﬁling experi-
ments were performed at the Bioninformatics and Gene expression
Analysis (BEA) core facility of the Karolinska Institutet (www.bea.ki.se).
Microarray data are deposited at GEO with the accession number
GSE73035.
2.4. Western blot analysis
Protein extracts were prepared in RIPA buffer (50 mM TriseHCl pH 7.4,
150 mM NaCl, 0.1% SDS, 1% NP-40, 1% Na deoxycholate, 1 mM
EDTA) supplemented with 1 mM DTT, 0.5 mM PMSF, and 1 mM so-
dium orthovanadate. Protein extracts (50 mg) were resolved by SDS
polyacrylamide gel electrophoresis and transferred into polyvinylidene
diﬂuoride membranes. Immunoblotting was performed with antibodiesMOLECULAR METABOLISM 4 (2015) 891e902  2015 The Authors. Published by Elsevier GmbH. This is an o
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phospho-AKT (Ser473) (Cell Signaling), diluted in 0.1% BSA. Quanti-
ﬁcation was performed using ImageJ [21].
2.5. Neutral lipid staining
Hepatocytes were ﬁxed with 4% paraformaldehyde for 10 min at room
temperature. After 3 washes with PBS, cells were incubated for 2 min
in 60% isopropanol and stained with freshly prepared Oil Red-O so-
lution (0.4% in 60% isopropanol) for 30 min at room temperature. Cells
were washed with PBS, incubated for 2 min with 300 nM 40,6-
diamidino-2-phenylindole, dihydrochloride (DAPI) (Life Technologies),
and washed with PBS again. Images were taken at a 200 magni-
ﬁcation. Total red and blue pixels were quantiﬁed using the Color
Range Select tool in Adobe Photoshop CS5.1.
2.6. Lipid proﬁling
Hepatocytes were incubated with 0.2 mCi/mL [U-14C] palmitate (Perkin
Elmer, USA) and 25 nM non-radioactive palmitate for 4 h. Lipids were
extracted, separated by thin layer chromatography, detected by
autoradiography, and quantiﬁed as previously described [22].
2.7. FA oxidation assay
Hepatocytes were incubated in DMEM supplemented with 1 g/L
glucose, 12.5 mM BSA-conjugated palmitic acid (Sigma Aldrich), and
2.5 mCi palmitic acid [9,10-3H(N)] (Perkin Elmer, USA). Four hours
later, 0.2 mL of media were collected to 2 mL tubes containing 0.8 mL
of activated charcoal slurry. Samples incubated at room temperature
for 30 min with frequent mixing. After centrifugation at 13,000 rpm for
15 min, 0.2 mL of supernatant were transferred to 4 mL scintillation
vials containing 2.8 mL of Ultima FLO M scintillation liquid (Perkin
Elmer, USA) and measured in a Wallac Winspectral 1414 liquid scin-
tillation counter. Cells were lysed in 0.03% SDS and protein concen-
tration was determined for each lysate. The FA oxidation rate was
normalized by cellular protein content.
2.8. Metabolite analysis by mass spectrometry
Metabolite analysis was done according to standard mass spectrom-
etry procedures [23]. Brieﬂy, metabolites were isolated from N2 frozen
hepatocytes by a FastPrep (3  6.5 M/s for 60 s) in a MeOH-Chlor-
ophorm-H2O suspension according to Wu et al. [24]. Extracted me-
tabolites were mixed with an internal standard consisting of
chloramphenicol; L-proline 1,2,3,4,5e13C5-, 2-15N-; L-glutamine
13C5; L-arginine C13N15; uracil 1,3e15N2-, 2-13C- and L-valine,
2,3,4,4,4,5,5,5-d8-, 100 mM each. Three MRM’s of each metabolite
were run as triplicates on an online coupled LC-MS/MS system (1290
Inﬁnity UHPLC, Agilent, USA; QTrap 6500, ABSciex, Canada) featuring a
Reprosil-PUR C18-AQ (1.9 mm, 120 Å, 150  2 mm ID; Dr. Maisch,
Germany) column and a zicHILIC (3.5 mm, 100 Å, 150  2.1 mm ID;
di2chrom, Germany) column at 30 C. Transitions were monitored and
acquired at low resolution in quadrupole Q1 and unit resolution in Q3.
Data acquisition was performed with an ion spray voltage of 5.5 kV in
positive and 4.5 kV in negative mode of the ESI source, N2 as collision
gas was set to high, curtain gas to 30 psi, ion source gas 1 and 2 to 50
and 70 psi, and an interface heater temperature of 350 C, operated
with AB Sciex Analyst 1.6.1 software with components for 6500 series
instruments. Quantiﬁcation was performed using MultiQuantTM soft-
ware v.2.1.1 (AB Sciex, USA) using appropriate internal controls for
technical validation. Integration settings were a Gaussian smooth width
of 2 points and a peak splitting factor of 2. Peak integrations were
reviewed manually and subsequent data analysis was done using
Ingenuity Pathway Analysis software suite.pen access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 893
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Glucose output was measured as previously described [25]. For b-OHB
output, media was changed to phenol red-free DMEM (5 g/L glucose)
24 h post-transduction and cells incubated for 16 h. Media was
collected and b-OHB levels were measured with the b-OHB Assay Kit
(Abcam) according to the manufacturer’s instructions. Both glucose
and b-OHB levels were normalized by cellular protein content
(extracted in 0.03% SDS).
2.10. Animal experimentation
C57BL/6J male mice were purchased from Charles River Laboratories
(Sulzfeld, Germany) and housed in a 12 h light/dark cycle with free
access to food and water. Unless otherwise stated, we used 9e10
week-old male C57BL/6J mice for all experiments. In all experiments,
mice were euthanized by cervical dislocation and tissues were rapidly
harvested and snap-frozen in liquid nitrogen. All experimental pro-
tocols were approved by the Regional Animal Ethics Committee of
Northern Stockholm or the Ethical Committee for Animal Experiments
of the University of Groningen.
2.10.1. Fasting/Refeeding
Mice (n ¼ 5) were fasted for 14 h, beginning at 17:00. Mice in the
refeeding group (n ¼ 7) were fasted at the same time but given free
access to food for 3 h following fasting. The respective controls (n ¼ 5
each) were euthanized at the same time but had continuous access to
food.
2.10.2. High fat diet
Mice (n ¼ 5 each) were fed normal chow or a high fat diet (TD.93075,
Harlan, USA) for one week.
2.10.3. Treadmill running
Mice (n ¼ 6) did not follow any exercise protocol. Treadmill runners
(n ¼ 8) followed the acclimation protocol detailed in Table S2.
Acclimation and running sessions began at 18:30. After acclima-
tion, mice were placed on a motorized treadmill (Columbus In-
struments, USA), with a slope of 5% and warmed-up for 5 min at
5 m/min. The speed was increased (5 m/min every 5 min) up to
20 m/min. Speeds varied between 15 and 20 m/min during the
experiment to allow mice to keep up with the protocol. Mice ran for
1 h or until exhaustion. We considered exhaustion as the total in-
capacity to keep up with the running pace even when the speed
was lowered to 15 m/min. Mice were euthanized immediately after
running.
2.10.4. Chronic exercise
Mice (n ¼ 6 each) were given free access to a running wheel for 8
weeks as previously described [26].
2.10.5. Adenovirus-mediated gene delivery to mouse liver
Age-matched, male whole-body Fxr/ mice [27] on a C57BL/6J
background received 5  109 adenoviral particles in PBS into the
retro-orbital sinus (n ¼ 5e6 per group). Five days post-transduction,
mice were fasted for 8 h prior to termination.
2.11. Analytical procedures
Plasma TAG and b-OHB levels were determined using commercially
available kits (Abcam). Liver TAGs were extracted in 5% NP-40 and
quantiﬁed with the same kit (Abcam).894 MOLECULAR METABOLISM 4 (2015) 891e902  2015 The Authors. Published by Elsevier Gmb2.12. Quantiﬁcation of Fxra2/Fxra1 relative expression
The method used to quantify the Fxra2/Fxra1 ratios was based on the
one described by Chen, Y et al. [14]. A fragment from Fxra1þFxra2
was ampliﬁed by PCR using a forward primer speciﬁc for Fxra1/a2 (50-
TCTCTGGCCCAAAGCAATCCAA-30) and a reverse primer speciﬁc for Fxr
(all isoforms; 50-TGAAAATCTCCGCCGAACGA-30). The ampliﬁed frag-
ment encompasses the 12 bp insert present in Fxra1 (but not a2),
which creates a BstZ17I restriction site that discriminates Fxra1 from
a2. The ampliﬁcation products were digested with BstZ17I and the
resulting fragment pattern was resolved by agarose electrophoresis
and quantiﬁed using ImageJ [21].
2.13. Statistical analysis
Statistical analysis was performed using Prism software. Two-tailed,
unpaired Student’s t-test was used to analyze statistical differences
between groups. Statistical signiﬁcance was deﬁned as p < 0.05
3. RESULTS
3.1. FXR isoform-speciﬁc target gene regulation
FXR variants possess structural differences suggestive of non-
overlapping biological functions (Figure 1A). To investigate the ef-
fect(s) of such variation on FXR-mediated transcriptional regulation and
hepatic metabolism, we expressed each human FXR isoform in mouse
primary hepatocytes. To this end, we generated recombinant adeno-
virus expressing from independent promoters GFP and each human
FXR isoform, or GFP alone (control). Transduction of hepatocytes with
the different adenovirus elevated total FXR mRNA and protein to similar
levels (Figure 1B,C). Remarkably, even well characterized FXR target
genes, including small heterodimer partner (Shp) or Bsep [28,29],
were regulated in an isoform-dependent manner (Figure 1D). The
expression of basic helix-loop-helix family member e41 (Bhlhe41/
Dec2/Sharp1), shown to repress FXR transactivation [30], was
increased by isoforms containing the MYTG motif in the hinge region
(FXRa1 and a3) but not by variants lacking this feature (FXRa2 and
a4). To evaluate the transcriptional networks regulated by each FXR
isoform, we proﬁled global gene expression in hepatocytes expressing
each FXR variant. By comparing genes regulated by each FXR isoform
with the GFP control, we generated the heat map presented in
Figure 1E and the principal component analysis plot in Figure S1A.
Both analyses indicated that FXR isoforms lacking the MYTG motif (a2
and a4) regulated much larger gene sets than their MYTG-containing
counterparts. Strikingly, from over 8,500 genes regulated by FXRs,
only 171 genes were coregulated by all isoforms (Figure S1B). Gene
set comparison revealed that together FXRa2 and a4 modulate the
expression ofw7,800 genes, 42% of which are coregulated by both
variants (Figure S1C). Bioinformatic pathway analysis identiﬁed sig-
niﬁcant associations between all FXR variants and key hepatic meta-
bolic functions and pathologies (Figure 1F and S1D). Further analysis of
the gene expression data, taking into consideration whether a
particular pathway or function was predicted to be activated or
repressed, suggested contrasting effects of FXR splice variants on
hepatic lipid metabolism (Figure 1G). The transcriptional programs
driven by FXRa2 and a4 were predicted to increase lipid/fatty acid (FA)
oxidation and decrease lipid/acylglycerol concentration, whereas the
opposite effect was predicted for the gene programs regulated by
FXRa1 and a3. These results show that FXR splice variants regulate
distinct transcriptional programs that can impact hepatic energy
metabolism.H. This is an open accessarticle under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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3.2. FXRa2 and a4 reduce hepatocyte lipid accumulation and
increase insulin responsiveness
Gene expression proﬁling suggested that FXR splicing variants may
have contrasting effects on hepatic lipid metabolism, with possible
repercussions on intracellular lipid accumulation. To pinpoint the gene
program(s) mediating the putative effects of FXRs on hepatic fat
storage, we analyzed the expression of key mediators of liver lipid
metabolism. We observed minor isoform speciﬁcity over lipogenic
gene expression (Figure S2A). However, FXRa2 and a4 increased the
expression of several hepatic lipases (Figure 2A). These include adi-
pose triglyceride lipase (Atgl), hormone-sensitive lipase (Hsl), and
carboxylesterase 1 g (Ces1g), together with Atgl’s coactivator
comparative gene identiﬁcation 58 (Cgi-58), all shown to decrease
hepatic lipid accumulation [31e33]. In addition, these FXR variantsFigure 2: FXRa2 and FXRa4 reduce hepatocyte lipid content and increase insulin se
(control) or together with each FXR variant. (A) Gene expression analysis by qRT-PCR. (B) Tr
lipid accumulation by Oil Red O (ORO) staining. Hepatocytes were cultured without (C) or w
(DAPI, blue), followed by quantiﬁcation (E). Scale bar, 50 mm. (F) Lipid proﬁling by TLC. (G)
values and error bars represent SEM (n  3). *p < 0.05 vs. control. #p < 0.05 vs. all o
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regulates intracellular FA trafﬁcking and reduces free fatty acid (FFA)
lipotoxicity [34]. To determine whether the changes in gene expression
elicited by FXRa2 and a4 effectively translate into a biological outcome
of reduced lipid accumulation, we evaluated intracellular lipid storage
in hepatocytes expressing each FXR isoform or GFP alone. This
revealed a robust reduction in lipid accumulation only in hepatocytes
expressing FXRa2 and a4 (Figure 2B,C). A sustained increase in
circulating FFA levels can lead to hepatic steatosis and insulin resis-
tance [35]. To investigate whether FXRs exert a protective effect
against hepatic lipid accumulation upon elevated FFA supply, we
treated hepatocytes expressing each FXR variant with palmitate.
Indeed, FXRa2 and a4 largely protected hepatocytes against
palmitate-induced lipid accumulation, reducing neutral lipid staining bynsitivity. (AeG) Hepatocytes were transduced with adenoviruses expressing GFP alone
ansduction monitoring by ﬂuorescence microscopy. Scale bar, 50 mm. (CeE) Analysis of
ith (D) palmitate treatment and stained for neutral lipids (ORO, red) and genomic DNA
Immunoblot for total AKT and p-AKT (ser473) in response to insulin. Bars depict mean
ther isoforms. Up < 0.05 vs. FXRa1/a2. xp < 0.05 vs. FXRa1/a3.
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lipid proﬁle of hepatocytes expressing each FXR variant, we used 14C-
palmitate thin layer chromatography (Figure 2D). In line with the
reduced lipid content, FXRa2 decreased 14C-palmitate incorporation
into TAG and diacylglycerol (DAG). This is unlikely to stem from
reduced palmitate uptake or DAG/TAG biosynthesis, since the main FA
transport proteins and TAG biosynthesis enzymes were expressed to
similar or higher levels in hepatocytes expressing FXRa2 (Figure S2B)
On the other hand, FXRa1 induced a small reduction in radiolabeled
DAG content without affecting radiolabeled TAG levels. Both FXRa1
and a2 decreased radiolabeled cholesteryl ester levels, which tended
to increase in cells expressing FXRa3 (32%, p ¼ 0.17). Under these
conditions, FXRa4 did not affect 14C-palmitate incorporation into any of
the lipid species analyzed. Hepatic lipid accumulation has been
extensively implicated in the development of hepatic insulin resistance
[35,36], which prompted us to investigate possible FXR effects on
insulin sensitivity. In line with decreased intracellular lipid content and
radiolabeled DAG and TAG levels, FXRa2 expression increased insulin-
stimulated AKT phosphorylation, indicative of enhanced insulin
sensitivity (Figure 2E). FXRa4 expression also resulted in enhanced
insulin-stimulated AKT phosphorylation, although to a lesser extent
than FXRa2. These results show that FXRa2 (and to a lesser extent
FXRa4) exert a positive effect on cellular insulin signaling to AKT, likely
due to reduced lipid accumulation.
3.3. FXRa2 promotes FA oxidation and ketogenesis
The FXR isoform-speciﬁc effects on hepatic lipid metabolism correlate
with the presence or absence of the splicing-regulated hinge region
MYTG motif. Since FXRa1 and a2 are the main isoforms in human liver
[11,14], we focused on these variants and further investigated their
role in hepatic metabolism. To better understand their effects on
cellular metabolic ﬂuxes, we performed unbiased metabolomics
analysis of hepatocytes expressing FXRa1, FXRa2, or GFP alone. We
observed increased levels of tricarboxylic acid (TCA) cycleFigure 3: FXRa2 promotes FA oxidation and b-OHB production. (AeF) Hepatocytes
Metabolomics analysis. Metabolite levels (A) and amino acid proﬁle (B) determined by ma
relative to control. Amino acids are grouped according to their potential for gluconeogenesi
(C), b-OHB release (D), and glucose output (E). (F) Gene expression analysis by qRT-PCR of
depict mean values and error bars represent SEM (n  3). *p < 0.05 compared to cont
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FXRa2 and to a lesser extent FXRa1 (Figure 3A). Furthermore, FXRa2
expression increased intracellular b-hydroxybutyric acid content,
whereas FXRa1 had the opposite effect. Free coenzyme A and NADþ,
two byproducts of the ketogenesis pathway, were also increased by
FXRa2, but not a1. Adding to this, FXRa2 promoted marked changes
in the hepatocyte amino acid proﬁle, particularly in amino acids
involved in ketone body production (Figure 3B and S3A). From bio-
informatic pathway analysis we identiﬁed signiﬁcant associations
between both FXR variants and metabolic pathways with predominant
roles in hepatic bioenergetics, including TCA cycle, gluconeogenesis,
ketogenesis, and FA b-oxidation (Figure S3B). Furthermore, this
analysis predicted increased lipid oxidation, mitochondrial respiration,
and reactive oxygen species production/metabolism in hepatocytes
expressing FXRa2 (Figure S3C). Thus, our metabolomics analysis
suggested that the gene program activated by FXRa2 leads to
increased FA oxidation and that the acetyl-CoA generated is not only
channeled through the TCA cycle but also directed towards ketone
body production. In agreement, we could verify that FXRa2 expression
increased cellular FA oxidation (Figure 3C) and b-hydroxybutyrate (b-
OHB) release (Figure 3D), whereas FXRa1 enhanced FA oxidation only
marginally and did not affect b-OHB release. Glucose output was not
affected by either FXR variant (Figure 3E). Consistent with these re-
sults, FXRa2 activated the expression of key transcriptional regulators
of FA metabolism, namely peroxisome proliferator-activated receptor-
a (Ppara) and cAMP-responsive element binding protein 3-like 3
(Creb3l3) (Figure 3F). Moreover, hepatocytes expressing FXRa2 had
increased levels of several acylcarnitines (Figure S3D), accompanied
by elevated carnitine palmitoyltransferase 1a (Cpt1a) and carnitine/
acylcarnitine translocase-like (Slc25a29) expression (Figure 3F).
FXRa2 also induced the expression of the mitochondrial uncoupling
proteins Ucp2 and Slc25a47, as well as the major ketogenic enzymes
3-hydroxy-3-methylglutaryl-CoA synthase 2 (Hmgcs2) and 3-
hydroxybutyrate dehydrogenase type 1 (Bdh1). On the other hand,were transduced with GFP alone (control) or together with FXRa1 or FXRa2. (AeB)
ss spectrometry. Graphs show metabolite levels in cells expressing FXRa1 or FXRa2
s (blue), ketogenesis (red), or both (green) (n ¼ 1). (CeE) Metabolic ﬂuxes. FA oxidation
key mediators of hepatic FA oxidation, mitochondrial uncoupling and ketogenesis. Bars
rol (GFP) or between the indicated groups.
H. This is an open accessarticle under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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FXRa1 activated the transcription of some of the above-mentioned
genes, but to a much lesser extent (Figure 3F). Taken together, our
results indicate that FXRa2 (but not a1) activates a comprehensive
gene program that promotes mobilization cellular lipid stores for b-
oxidation and, at least in part, ketone body production.
3.4. Changing FXRa2/a1 ratios promotes transcriptional
reprogramming
Bile acids function as endogenous FXRs ligands and greatly increase
their capacity to transcriptionally activate a vast array of target genes
[2,3]. However, alternative endogenous ligands and ligand-
independent FXR activity have also been reported [13,37]. To inves-
tigate whether bile acids affect the gene program under FXRa2 control,Figure 4: Changing FXRa2/a1 ratios promotes transcriptional reprogramming. (A) Ta
treated with vehicle (DMSO) or 250 mM cholic acid (CA) for 24 h. Bars depict mean values a
the indicated groups. (B) Gene expression analysis by qRT-PCR in hepatocytes co-transd
30%; , 0%). Graphs represent expression levels relative to hepatocytes transduced w
*p < 0.05 compared to FXRa1 alone or between the indicated groups.
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cholic acid (CA), a concentration shown to yield moderate FXR acti-
vation [38]. CA treatment in GFP-transduced cells decreased the
expression of most FXRa2 target genes involved in lipolysis, FA
oxidation, mitochondrial uncoupling, and ketogenesis (Figure 4A and
Figure S4A). The exceptions were Atgl, Hsl, Cgi-58, and Fabp1, whose
expression was not affected by CA treatment. In contrast, when FXRa2
expression was increased, only Ucp2, Hmgcs2 and to a lesser extent
Ppara displayed reduced mRNA levels upon CA treatment, when
compared to vehicle-treated cells. For all other genes analyzed,
expression was unchanged or in some cases (e.g. Atgl and Slc25a47)
enhanced by CA treatment. Interestingly, increased FXRa2 levels
blunted the CA-mediated effects on Bhlhe41 expression.rget gene expression analysis by qRT-PCR in hepatocytes expressing GFP or FXRa2 and
nd error bars represent SEM (n ¼ 5). *p < 0.05 compared to vehicle-treated or between
uced with FXRa1 and FXRa2 in different proportions (þþþ, 100%; þþ, 70%; þ,
ith FXRa1 alone. Graphs depict mean values and error bars represent SEM (n ¼ 5).
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splice isoforms has important implications on hepatic metabolism
[11,14,18]. To verify whether changing FXRa2/a1 ratios is sufﬁcient to
promote transcriptional reprogramming, we co-expressed different
proportions of FXRa1:FXRa2 in hepatocytes. For clarity, the relative
amounts of FXRa1 and a2 adenoviral particles used are illustrated in
Figure 4B. While maintaining similar total FXR expression levels,
increasing FXRa2/a1 ratios gradually induced the FXRa2-mediated
gene program conducive to increased lipolysis, FA oxidation and
ketogenesis (Figure 4B and S4B). Bhlhe41 expression showed the
opposite pattern. These data indicate that changes in FXR isoform
composition through alternative splicing can promote transcriptional
reprogramming and alter hepatic lipid handling and ketogenic
capacity.
3.5. FXRa1 and a2 regulate discrete gene programs in vivo
We then sought to determine the gene programs regulated by each
FXR variant in mouse liver. As expected, both FXR variants robustly
activated Bsep and Shp transcription and reduced Cyp7a1 expression
(Figure 5I). In terms of lipolytic factors, Hsl and Ces1g expression was
increased by both FXRs, whereas Cgi-58 transcription was only acti-
vated by FXRa2 (Figure 5J). We observed no differences in Atgl mRNA
levels and Mgl expression was decreased by both FXR variants. This
likely reﬂects a decreased reliance on intracellular fat stores in face of
a constant FFA supply from circulation, unlike cultured hepatocytes,Figure 5: FXRa2 improves hepatic lipid handling in vivo. (AeL) Adenovirus-mediated
protein levels in liver determined by western blot. (BeH) Box plots of body weight (B), liver
and plasma b-OHB (H) levels in Fxr/ following FXRs gene delivery. (IeL) Gene express
transport and catabolism (K) and lipogenesis (L). Bars depict mean values and error bars re
groups.
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line with the results obtained in hepatocytes, FXRa2 activated the
expression of a vast array of genes with key roles in FA uptake (Fabp1,
2 and 5) and oxidation (Creb3l3, Ppara, Cpt1a, and Slc25a29), mito-
chondrial uncoupling (Ucp2 and Slc25a47), and ketogenesis (Bdh1)
(Figure 5K). On the other hand, FXRa1 had marginal regulatory effects
on this gene program, since only Creb3l3 was signiﬁcantly induced by
this variant. Instead, FXRa1 markedly reduced lipogenic gene
expression, as evidenced by decreased pyruvate kinase (Pklr), acetyl-
CoA carboxylase alpha (Acc-1), FA synthase (Fasn), stearoyl-CoA
desaturase 1 (Scd1), and liver X receptor b (Lxrb) mRNA levels
(Figure 5L). In contrast, FXRa2 did not regulate lipogenic gene
expression. Our results show that FXRa1 and a2 regulate distinct
transcriptional programs in mouse liver, which inﬂuences their ca-
pacity to reduce hepatic steatosis.
3.6. Liver Fxr splicing is dynamically regulated by systemic
metabolic demands
Our data indicate that FXRa1 and a2 regulate discrete gene programs
in liver and that changing the FXRa2/a1 ratio is sufﬁcient to promote
transcriptional reprogramming and alter hepatic lipid metabolism. This
could constitute a molecular mechanism of hepatic adaptation to
increased energetic demands. To test this hypothesis, we investigated
if Fxr splicing is altered by fasting when hepatic metabolism is
modulated to handle higher lipid inﬂux and meet systemic energeticFXRa1 and FXRa2 gene delivery to Fxr/ mice liver. (A) Experimental design and FXR
weight (C), liver/body weight ratio (D), blood glucose (E), plasma TAG (F), liver TAG (G),
ion analysis by qRT-PCR of genes involved in bile acid metabolism (I), lipolysis (J), FA
present SEM (n ¼ 5e6). *p < 0.05 compared to control (GFP) or between the indicated
H. This is an open accessarticle under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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demands. Indeed, fasting increased liver Fxra2/a1 ratios, which
dropped below fed control levels upon refeeding (Figure 6A). Physical
exercise also promotes rapid and profound changes in hepatic
metabolism, by increasing FA oxidation and ketogenesis [39,40]. To
test whether Fxr splicing plays a role in hepatic adaptions to exercise,
we evaluated whether Fxra2/a1 ratios changed in response to acute
and chronic exercise. A single bout of strenuous exercise was sufﬁ-
cient to change the relative levels of Fxr variants in the liver (Figure 6B).
Mice challenged with a treadmill run to exhaustion had higher Fxra2/
a1 ratios than non-exercised controls. To investigate if regular,
moderate exercise exerts similar effects on liver Fxr splicing, mice
were given access to a running wheel for 8 weeks. After this milder but
longer exercise protocol, the exercised group had higher Fxra2/a1
ratios than sedentary controls (Figure 6C). Elevated FFA efﬂux from
adipose tissue is characteristic of both fasting and physical exercise.
Hence, Fxr splicing could be responsive to elevated FA supply and elicit
an adaptive response to improve liver lipid handling capacity. Indeed,
increased hepatic FA oxidation and TCA cycle turnover have been
reported in obese mice and humans, likely reﬂecting an adaptive
response to elevated hepatic lipid inﬂux [41,42]. Thus, we investigated
whether high fat feeding modulates liver Fxr splicing. After one week of
high fat feeding, sufﬁcient to induce hepatic steatosis in rodents [36],Figure 6: Systemic bioenergetic demands change Fxra2/a1 ratios. (AeD) Hepatic
Fxra2/a1 splicing in response to metabolic stressors. Graphs represent box plots of
Fxra2/a1 ratios relative to controls upon overnight fasting and 3 h after refeeding
(n ¼ 7) (A), a single bout of intensive exercise on a treadmill for 1 h or until exhaustion
(n ¼ 6e8) (B), eight weeks of voluntary exercise in running wheels (n ¼ 6) (C), and one
week on a high fat diet (n ¼ 5) (D). *p < 0.05 compared to control or between the
indicated groups.
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(Figure 6D). These results indicate that Fxr splicing changes in
response to elevated energetic demands and coordinates an adaptive
response conducive to improved lipid handling/disposal through
enhanced lipolysis, FA oxidation and ketogenesis.
4. DISCUSSION
Hepatic lipid accumulation is a hallmark of NAFLD and associated
pathologies. The molecular mechanisms mediating this metabolic
disarray remain largely unknown. Consequently, current NAFLD
treatments target the metabolic symptoms rather than the underlying
mechanisms. Due to its beneﬁcial effects on hepatic lipid homeostasis,
FXR is a promising target for the treatment of NAFLD. However, FXR
consists of four distinct proteins and little is known about the biological
functions of each variant.
We show here that FXR isoforms drive distinct gene programs in he-
patocytes and liver, with speciﬁc biological outcomes. Our data indi-
cate that a “MYTG” amino acid sequence in the hinge region of some
FXR variants is a major determinant of transcriptional and biological
activity. We observed that variants lacking this motif (FXRa2 and a4)
regulate much larger gene sets than the MYTG-containing counter-
parts. In line with this observation, the MYTG motif has previously been
shown to impair FXRs’ ability to transactivate speciﬁc reporter con-
structs [11,17,18,43]. The different N-termini of FXRa1/a2 and
FXRa3/a4 do not seem to signiﬁcantly inﬂuence the metabolic path-
ways addressed in this study but also underlie important changes in
FXR target gene activation. For example, FXRa1 and a2 activated Bsep
expression to a much greater extent than FXRa3 and a4. Accordingly,
Fxra2 and a4, which differ only in the N-termini, have been shown to
differentially modulate Bsep expression in mouse liver but decrease
hepatic TAG levels to similar extents [43]. Notably, only FXRa2 and a4
induced Atgl and Hsl expression, two lipases with key roles in hepatic
lipid homeostasis. Hepatic overexpression of Atgl or Hsl reduces liver
TAG levels in obese mice, without increasing plasma TAGs or apoli-
poprotein B secretion [31]. Conversely, Atgl loss-of-function aggra-
vates hepatic steatosis and inﬂammation [44,45], whereas Hsl
deﬁciency promotes liver cholesteryl ester accumulation [46]. FXRa2
and a4 also elevated Cgi-58 expression, an Atgl activator [32]. Acti-
vating this transcriptional program reduced hepatocyte basal and
palmitate-induced lipid accumulation and improved insulin
responsiveness.
Our metabolomics analysis suggested that the FA mobilized from
intracellular lipid stores were being channeled to mitochondrial FA
oxidation. Indeed, hepatocytes expressing FXRa2 oxidized 90% more
palmitate than controls. In support of this observation, FXRa2 activated
the expression of Ppara and Creb3l3, two important regulators of
hepatic FA metabolism with protective roles against obesity-associated
metabolic disarrays [47e50]. Moreover, FXRa2 increased acylcarni-
tine levels and Cpt1a and Slc25a29 expression, indicating increased
shuttling of FA to mitochondrial b-oxidation. Excessive TCA cycle
ﬂuxes have been reported in NAFLD patients and correlated with
increased gluconeogenesis [41]. However, neither FXR variant affected
hepatocyte glucose output. Instead, FXRa2 enhanced b-OHB pro-
duction and release by increasing both ketogenic gene expression and
substrate supply. This mechanism is in accordance with the reported
plasma b-OHB increase in mice expressing ectopic Atgl and Hsl [31].
In addition, hepatocytes expressing FXRa2 had higher mRNA levels of
the mitochondrial uncoupling proteins Ucp2 and Slc25a47, suggesting
that mitochondrial uncoupling may take place to sustain FA oxidation
ﬂuxes and alleviate oxidative stress [51,52].pen access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 899
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most of its reported effects are dependent on or potentiated by ligand-
mediated activation. In line with the increasingly recognized role of bile
acids as sensors of the feeding state [53,54], CA reduced the
expression of key mediators of FA oxidation, mitochondrial uncoupling,
and ketogenesis in hepatocytes. However, FXRa2 expression blunted
(or in some cases even reversed) most CA effects on these target
genes, when compared to hepatocytes expressing GFP alone. Thus,
our results indicate that in addition to bile acid-mediated activation,
FXR expression greatly inﬂuences target gene activation and biological
outcome. Indeed, reduced Fxr expression was shown to contribute to
hepatic metabolic dysfunction even in the presence of elevated hepatic
bile acid levels [4]. Conversely, Fxra2 expression in mouse liver im-
proves hepatic steatosis despite a slight decrease in the bile acid pool
[43]. Although FXRs can interact with coactivators and transactivate
target promoters in a ligand-independent manner [13], they have
ﬂexible ligand-binding pockets that accommodate ligands with diverse
structures [15,55] and alternative endogenous agonists have been
described [37]. Thus, other endogenous ligands may contribute to
FXRa2-mediated regulation of hepatic energy metabolism.
The relative expression of FXR splice variants affects its sum tran-
scriptional activity and biological function [11,14,43]. Hepatic FXRa2/
a1 ratios are decreased in hepatocellular carcinoma patients and by
tumor necrosis factor a and interleukin 6 [14], two cytokines associ-
ated with hepatic steatosis and insulin resistance [56e59]. It is
interesting to note that bioinformatic pathway analysis of both gene
microarray and metabolomics data predicted opposite roles for FXRa1
and a2 on liver cancer, with FXRa2 being protective. Our results
indicate that elevating the FXRa2/FXRa1 ratio in hepatocytes without
increasing total FXR levels is sufﬁcient to activate a broad energy-
mobilizing gene program, which can constitute an adaptive mecha-
nism to physiological settings of high systemic energetic demands. In
strong support of this notion, liver Fxra2/a1 ratios were increased
during fasting and rapidly decreased upon refeeding. Physical exercise
modulates bile acid homeostasis, reduces hepatic lipid accumulation
and is also associated with enhanced hepatic b-oxidation and keto-
genesis [39,40,60]. We found that aerobic exercise increases the liver
Fxra2/a1 ratio, supporting the idea that the beneﬁcial effects of ex-
ercise on hepatic lipid metabolism may involve changes in Fxr splicing.
In agreement with the results obtained with cultured hepatocytes,
FXRa2 expression in Fxr/mouse liver activated a broad set of genes
involved in lipolysis, FA oxidation, mitochondrial uncoupling, and
ketogenesis. Surprisingly, Atgl expression was not regulated by FXRa2
in vivo. Although the plentiful supply of FFA from circulation may
alleviate the dependence on intracellular lipid stores, it is important to
note that the expression of Cgi-58, which increases Atgl TAG hydrolase
activity up to 20-fold [32], was induced by FXRa2 and may contribute
for elevated lipolytic capacity. Indeed, Cgi-58 suppression alone cau-
ses hepatic steatosis, steatohepatitis, and ﬁbrosis [61,62], which
demonstrates its pivotal role in hepatic lipid metabolism. As a result of
these transcriptional adaptations, hepatic TAG levels were decreased
in mice transduced with FXRa2. Noteworthy, FXRa2 induced Fatp1
and Fatp5 expression, whereas Fatp2 was expressed to similar levels
compared to controls but higher than in livers transduced with FXRa1.
This indicates that the reduced TAG content in FXRa2-expressing livers
is not secondary to reduced hepatic FA uptake capacity. Although
FXRa2 expression in Fxr/ mouse liver was sufﬁcient to regulate
most of the pathways we observed in isolated hepatocytes, and reduce
lipid accumulation, it did not increase plasma b-OHB levels, likely due
to unchanged Hmgcs2 expression. FXRa1 decreased hepatic TAG
levels to a lesser extent and did so through distinct mechanisms. This900 MOLECULAR METABOLISM 4 (2015) 891e902  2015 The Authors. Published by Elsevier Gmbvariant had marginal effects on FXRa2-regulated genes but decreased
the expression of key mediators of de novo lipogenesis. Interestingly, in
cultured hepatocytes we observed minor isoform dependence in the
transcriptional control of de novo lipogenesis. FXR’s transcriptional
regulation of de novo lipogenesis has been previously shown to depend
on bile acid-mediated activation [63]. Thus, the decrease in lipogenic
gene expression observed in liver likely reﬂects FXRa1 activation by
endogenous bile acids, which did not occur in isolated hepatocytes.
These results clearly dissociate two different mechanisms by which
FXRa1 and a2 reduce hepatic steatosis.
Due to its prominent role in hepatic lipid metabolism, FXR has long
been suggested as a promising therapeutic target for NAFLD and other
hepatic metabolic disorders. Indeed, obeticholic acid, a potent FXR
agonist, improves insulin sensitivity and reduces liver inﬂammation
and ﬁbrosis in patients with NAFLD and type 2 diabetes [64]. More
recently, the FLINT clinical trial reported improved liver histology in
45% of non-alcoholic steatohepatitis patients treated with obeticholic
acid [65]. Our results show that the main FXR variants in human liver
(a1 and a2) regulate distinct liver gene programs, which may have
important clinical implications. In NAFLD, approximately 60% of he-
patic TAG content is derived from plasma FFA and only 26% from de
novo lipogenesis [66]. Therapeutic strategies speciﬁcally targeting
FXRa2 should offer advantages over classical pan-FXR activation.
Perhaps more importantly, our data show that FXR splicing in mouse
liver is modulated by feeding status and physical exercise, which may
modify the therapeutic response to pan-FXR agonists. This knowledge
could be rapidly translated into clinic practice to improve the thera-
peutic efﬁcacy of existing FXR agonists.
ACKNOWLEDGMENTS
This project was supported by grants from the Diabetes Wellness Network Sweden
(3848/2013SW) (JLR), Swedish Research Council (2014-3410, JLR; 2011-3550,
JRZ), Strategic Research Programme in Diabetes at Karolinska Institutet (SRPD-KI)
(JLR, JRZ), Novo Nordisk Foundation (Denmark, NNF12OC1016062) (JLR), Swedish
Diabetes Foundation (DIA2013-076, JLR; DIA2012-082, JRZ), Swedish Foundation
for Strategic Research (SRL10-0027) (JRZ), the European Research Council (233285)
(JRZ) and the European Union (MC CIG 294232, JLR; FP7-HEALTH nr.305707, AKG).
JCC was supported in part by a PhD fellowship from the Fundação para a Ciência e
Tecnologia (FCT, Portugal, SFRH/BD/44825/2008), VMR by a postdoctoral fellowship
from the Wenner-Gren Foundations (Sweden), JM by a Swedish Institute scholarship
(00303/2012), and IS by the SRPD-KI. VR was supported by FCT (Portugal, project
PEst-OE/EQB/LA0023/2013). DM and SS were supported by the German Ministry for
Education and Research (BMBF, grant number 0315082 (01EA1303)) and the Max
Planck Society. We thank Drs. Anna Krook, Alfredo Gimenez-Cassina and Peter Arner
(KI) for valuable scientiﬁc discussions.
CONFLICTS OF INTEREST
None declared.
APPENDIX A. SUPPLEMENTARY DATA
Supplementary data related to this article can be found at http://dx.doi.org/10.1016/j.
molmet.2015.09.005.
REFERENCES
[1] Loomba, R., Sanyal, A.J., 2013. The global NAFLD epidemic. Nature Reviews
Endocrinology & Hepatology 10(11):686e690.H. This is an open accessarticle under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
www.molecularmetabolism.com
[2] Parks, D.J., Blanchard, S.G., Bledsoe, R.K., Chandra, G., Consler, T.G.,
Kliewer, S.A., et al., 1999. Bile acids: natural ligands for an orphan nuclear
receptor. Science 284(5418):1365e1368.
[3] Makishima, M., Okamoto, A.Y., Repa, J.J., Tu, H., Learned, R.M., Luk, A.,
et al., 1999. Identiﬁcation of a nuclear receptor for bile acids. Science
284(5418):1362e1365.
[4] Lu, Y., Ma, Z., Zhang, Z., Xiong, X., Wang, X., Zhang, H., et al., 2014. Yin Yang
1 promotes hepatic steatosis through repression of farnesoid X receptor in
obese mice. Gut 63(1):170e178.
[5] Xiong, X., Wang, X., Lu, Y., Wang, E., Zhang, Z., Yang, J., et al., 2014. Hepatic
steatosis exacerbated by endoplasmic reticulum stress-mediated down-
regulation of FXR in aging mice. Journal of Hepatology 60(4):847e854.
[6] Yang, Z.X., Shen, W., Sun, H., 2010. Effects of nuclear receptor FXR on the
regulation of liver lipid metabolism in patients with non-alcoholic fatty liver
disease. Hepatology International 4(4):741e748.
[7] Sinal, C.J., Tohkin, M., Miyata, M., Ward, J.M., Lambert, G., Gonzalez, F.J.,
2000. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid
and lipid homeostasis. Cell 102(6):731e744.
[8] Ma, K., Saha, P.K., Chan, L., Moore, D.D., 2006. Farnesoid X receptor is
essential for normal glucose homeostasis. Journal of Clinical Investigation
116(4):1102e1109.
[9] Cipriani, S., Mencarelli, A., Palladino, G., Fiorucci, S., 2010. FXR activation
reverses insulin resistance and lipid abnormalities and protects against
liver steatosis in Zucker (fa/fa) obese rats. Journal of Lipid Research 51(4):
771e784.
[10] Zhang, Y., Lee, F.Y., Barrera, G., Lee, H., Vales, C., Gonzalez, F.J., et al., 2006.
Activation of the nuclear receptor FXR improves hyperglycemia and hyper-
lipidemia in diabetic mice. Proceedings of the National Academy of Sciences of
the United States of America 103(4):1006e1011.
[11] Zhang, Y., Kast-Woelbern, H.R., Edwards, P.A., 2003. Natural structural var-
iants of the nuclear receptor farnesoid X receptor affect transcriptional acti-
vation. The Journal of Biological Chemistry 278(1):104e110.
[12] Huber, R.M., Murphy, K., Miao, B., Link, J.R., Cunningham, M.R., Rupar, M.J.,
et al., 2002. Generation of multiple farnesoid-X-receptor isoforms through the
use of alternative promoters. Gene 290(1e2):35e43.
[13] Zhang, Y., Castellani, L.W., Sinal, C.J., Gonzalez, F.J., Edwards, P.A., 2004.
Peroxisome proliferator-activated receptor-gamma coactivator 1alpha (PGC-
1alpha) regulates triglyceride metabolism by activation of the nuclear receptor
FXR. Genes & Development 18(2):157e169.
[14] Chen, Y., Song, X., Valanejad, L., Vasilenko, A., More, V., Qiu, X., et al., 2013.
Bile salt export pump is dysregulated with altered farnesoid X receptor
isoform expression in patients with hepatocellular carcinoma. Hepatology
57(4):1530e1541.
[15] Downes, M., Verdecia, M.A., Roecker, A.J., Hughes, R., Hogenesch, J.B., Kast-
Woelbern, H.R., et al., 2003. A chemical, genetic, and structural analysis of the
nuclear bile acid receptor FXR. Molecular Cell 11(4):1079e1092.
[16] Howarth, D.L., Hagey, L.R., Law, S.H., Ai, N., Krasowski, M.D., Ekins, S., et al.,
2010. Two farnesoid X receptor alpha isoforms in Japanese medaka (Oryzias
latipes) are differentially activated in vitro. Aquatic Toxicology 98(3):245e255.
[17] Anisfeld, A.M., Kast-Woelbern, H.R., Meyer, M.E., Jones, S.A., Zhang, Y.,
Williams, K.J., et al., 2003. Syndecan-1 expression is regulated in an isoform-
speciﬁc manner by the farnesoid-X receptor. The Journal of Biological
Chemistry 278(22):20420e20428.
[18] Song, X., Chen, Y., Valanejad, L., Kaimal, R., Yan, B., Stoner, M., et al., 2013.
Mechanistic insights into isoform-dependent and species-speciﬁc regulation of
bile salt export pump by farnesoid X receptor. Journal of Lipid Research
54(11):3030e3044.
[19] Luo, J., Deng, Z.L., Luo, X., Tang, N., Song, W.X., Chen, J., et al., 2007.
A protocol for rapid generation of recombinant adenoviruses using the AdEasy
system. Nature Protocols 2(5):1236e1247.MOLECULAR METABOLISM 4 (2015) 891e902  2015 The Authors. Published by Elsevier GmbH. This is an o
www.molecularmetabolism.com[20] Estall, J.L., Ruas, J.L., Choi, C.S., Laznik, D., Badman, M., Maratos-Flier, E.,
et al., 2009. PGC-1alpha negatively regulates hepatic FGF21 expression by
modulating the heme/Rev-Erb(alpha) axis. Proceedings of the National Acad-
emy of Sciences of the United States of America 106(52):22510e22515.
[21] Schneider, C.A., Rasband, W.S., Eliceiri, K.W., 2012. NIH Image to ImageJ: 25
years of image analysis. Nature Methods 9(7):671e675.
[22] Massart, J., Zierath, J.R., Chibalin, A.V., 2014. A simple and rapid method to
characterize lipid fate in skeletal muscle. BMC Research Notes 7:391.
[23] Guo, B., Chen, B., Liu, A., Zhu, W., Yao, S., 2012. Liquid chromatography-
mass spectrometric multiple reaction monitoring-based strategies for
expanding targeted proﬁling towards quantitative metabolomics. Current Drug
Metabolism 13(9):1226e1243.
[24] Wu, H., Southam, A.D., Hines, A., Viant, M.R., 2008. High-throughput tissue
extraction protocol for NMR- and MS-based metabolomics. Analytical
Biochemistry 372(2):204e212.
[25] Lustig, Y., Ruas, J.L., Estall, J.L., Lo, J.C., Devarakonda, S., Laznik, D., et al.,
2011. Separation of the gluconeogenic and mitochondrial functions of PGC-1
{alpha} through S6 kinase. Genes & Development 25(12):1232e1244.
[26] Agudelo, L.Z., Femenia, T., Orhan, F., Porsmyr-Palmertz, M., Goiny, M.,
Martinez-Redondo, V., et al., 2014. Skeletal muscle PGC-1alpha1 modulates
kynurenine metabolism and mediates resilience to stress-induced depression.
Cell 159(1):33e45.
[27] Kok, T., Hulzebos, C.V., Wolters, H., Havinga, R., Agellon, L.B., Stellaard, F.,
et al., 2003. Enterohepatic circulation of bile salts in farnesoid X receptor-
deﬁcient mice: efﬁcient intestinal bile salt absorption in the absence of
ileal bile acid-binding protein. The Journal of Biological Chemistry 278(43):
41930e41937.
[28] Lu, T.T., Makishima, M., Repa, J.J., Schoonjans, K., Kerr, T.A., Auwerx, J.,
et al., 2000. Molecular basis for feedback regulation of bile acid synthesis by
nuclear receptors. Molecular Cell 6(3):507e515.
[29] Ananthanarayanan, M., Balasubramanian, N., Makishima, M.,
Mangelsdorf, D.J., Suchy, F.J., 2001. Human bile salt export pump promoter is
transactivated by the farnesoid X receptor/bile acid receptor. The Journal of
Biological Chemistry 276(31):28857e28865.
[30] Cho, Y., Noshiro, M., Choi, M., Morita, K., Kawamoto, T., Fujimoto, K., et al.,
2009. The basic helix-loop-helix proteins differentiated embryo chondrocyte
(DEC) 1 and DEC2 function as corepressors of retinoid X receptors. Molecular
Pharmacology 76(6):1360e1369.
[31] Reid, B.N., Ables, G.P., Otlivanchik, O.A., Schoiswohl, G., Zechner, R.,
Blaner, W.S., et al., 2008. Hepatic overexpression of hormone-sensitive lipase
and adipose triglyceride lipase promotes fatty acid oxidation, stimulates direct
release of free fatty acids, and ameliorates steatosis. The Journal of Biological
Chemistry 283(19):13087e13099.
[32] Lass, A., Zimmermann, R., Haemmerle, G., Riederer, M., Schoiswohl, G.,
Schweiger, M., et al., 2006. Adipose triglyceride lipase-mediated lipolysis of
cellular fat stores is activated by CGI-58 and defective in Chanarin-Dorfman
syndrome. Cell Metabolism 3(5):309e319.
[33] Quiroga, A.D., Li, L., Trotzmuller, M., Nelson, R., Proctor, S.D., Kofeler, H.,
et al., 2012. Deﬁciency of carboxylesterase 1/esterase-x results in obesity,
hepatic steatosis, and hyperlipidemia. Hepatology 56(6):2188e2198.
[34] Atshaves, B.P., Martin, G.G., Hostetler, H.A., McIntosh, A.L., Kier, A.B.,
Schroeder, F., 2010. Liver fatty acid-binding protein and obesity. The Journal
of Nutritional Biochemistry 21(11):1015e1032.
[35] Samuel, V.T., Liu, Z.X., Qu, X., Elder, B.D., Bilz, S., Befroy, D., et al., 2004.
Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease.
The Journal of Biological Chemistry 279(31):32345e32353.
[36] Samuel, V.T., Liu, Z.X., Wang, A., Beddow, S.A., Geisler, J.G., Kahn, M., et al.,
2007. Inhibition of protein kinase Cepsilon prevents hepatic insulin resistance
in nonalcoholic fatty liver disease. Journal of Clinical Investigation 117(3):
739e745.pen access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 901
Original article[37] Zhao, A., Yu, J., Lew, J.L., Huang, L., Wright, S.D., Cui, J., 2004. Poly-
unsaturated fatty acids are FXR ligands and differentially regulate expression
of FXR targets. DNA and Cell Biology 23(8):519e526.
[38] Lew, J.L., Zhao, A., Yu, J., Huang, L., De Pedro, N., Pelaez, F., et al., 2004.
The farnesoid X receptor controls gene expression in a ligand- and promoter-
selective fashion. The Journal of Biological Chemistry 279(10):8856e8861.
[39] Rector, R.S., Thyfault, J.P., Morris, R.T., Laye, M.J., Borengasser, S.J.,
Booth, F.W., et al., 2008. Daily exercise increases hepatic fatty acid oxidation and
prevents steatosis in Otsuka Long-Evans Tokushima fatty rats. American Journal
of Physiology - Gastrointestinal and Liver Physiology 294(3):G619eG626.
[40] Kim, K.H., Kim, S.H., Min, Y.K., Yang, H.M., Lee, J.B., Lee, M.S., 2013. Acute
exercise induces FGF21 expression in mice and in healthy humans. PLoS One
8(5):e63517.
[41] Sunny, N.E., Parks, E.J., Browning, J.D., Burgess, S.C., 2011. Excessive he-
patic mitochondrial TCA cycle and gluconeogenesis in humans with nonal-
coholic fatty liver disease. Cell Metabolism 14(6):804e810.
[42] Satapati, S., Sunny, N.E., Kucejova, B., Fu, X., He, T.T., Mendez-Lucas, A.,
et al., 2012. Elevated TCA cycle function in the pathology of diet-induced
hepatic insulin resistance and fatty liver. Journal of Lipid Research 53(6):
1080e1092.
[43] Boesjes, M., Bloks, V.W., Hageman, J., Bos, T., van Dijk, T.H., Havinga, R.,
et al., 2014. Hepatic farnesoid X-receptor isoforms alpha2 and alpha4
differentially modulate bile salt and lipoprotein metabolism in mice. PLoS One
9(12):e115028.
[44] Wu, J.W., Wang, S.P., Alvarez, F., Casavant, S., Gauthier, N., Abed, L., et al.,
2011. Deﬁciency of liver adipose triglyceride lipase in mice causes progressive
hepatic steatosis. Hepatology 54(1):122e132.
[45] Jha, P., Claudel, T., Baghdasaryan, A., Mueller, M., Halilbasic, E., Das, S.K.,
et al., 2014. Role of adipose triglyceride lipase (PNPLA2) in protection from
hepatic inﬂammation in mouse models of steatohepatitis and endotoxemia.
Hepatology 59(3):858e869.
[46] Sekiya, M., Osuga, J., Yahagi, N., Okazaki, H., Tamura, Y., Igarashi, M., et al.,
2008. Hormone-sensitive lipase is involved in hepatic cholesteryl ester hy-
drolysis. Journal of Lipid Research 49(8):1829e1838.
[47] Kersten, S., Seydoux, J., Peters, J.M., Gonzalez, F.J., Desvergne, B.,
Wahli, W., 1999. Peroxisome proliferator-activated receptor alpha mediates
the adaptive response to fasting. Journal of Clinical Investigation 103(11):
1489e1498.
[48] Abdelmegeed, M.A., Yoo, S.H., Henderson, L.E., Gonzalez, F.J.,
Woodcroft, K.J., Song, B.J., 2011. PPARalpha expression protects male mice
from high fat-induced nonalcoholic fatty liver. The Journal of Nutrition 141(4):
603e610.
[49] Nakagawa, Y., Satoh, A., Yabe, S., Furusawa, M., Tokushige, N., Tezuka, H.,
et al., 2014. Hepatic CREB3L3 controls whole-body energy homeostasis and
improves obesity and diabetes. Endocrinology 155(12):4706e4719.
[50] Staels, B., Rubenstrunk, A., Noel, B., Rigou, G., Delataille, P., Millatt, L.J.,
et al., 2013. Hepatoprotective effects of the dual peroxisome proliferator-
activated receptor alpha/delta agonist, GFT505, in rodent models of nonal-
coholic fatty liver disease/nonalcoholic steatohepatitis. Hepatology 58(6):
1941e1952.
[51] Jin, X., Yang, Y.D., Chen, K., Lv, Z.Y., Zheng, L., Liu, Y.P., et al., 2009. HDMCP
uncouples yeast mitochondrial respiration and alleviates steatosis in L02 and
hepG2 cells by decreasing ATP and H2O2 levels: a novel mechanism for
NAFLD. Journal of Hepatology 50(5):1019e1028.
[52] Serviddio, G., Bellanti, F., Tamborra, R., Rollo, T., Capitanio, N., Romano, A.D.,
et al., 2008. Uncoupling protein-2 (UCP2) induces mitochondrial proton leak902 MOLECULAR METABOLISM 4 (2015) 891e902  2015 The Authors. Published by Elsevier Gmband increases susceptibility of non-alcoholic steatohepatitis (NASH) liver to
ischaemia-reperfusion injury. Gut 57(7):957e965.
[53] Seok, S., Fu, T., Choi, S.E., Li, Y., Zhu, R., Kumar, S., et al., 2014. Tran-
scriptional regulation of autophagy by an FXR-CREB axis. Nature 516(7529):
108e111.
[54] Lee, J.M., Wagner, M., Xiao, R., Kim, K.H., Feng, D., Lazar, M.A., et al., 2014.
Nutrient-sensing nuclear receptors coordinate autophagy. Nature 516(7529):
112e115.
[55] Jin, L., Feng, X., Rong, H., Pan, Z., Inaba, Y., Qiu, L., et al., 2013. The anti-
parasitic drug ivermectin is a novel FXR ligand that regulates metabolism.
Nature Communications 4:1937.
[56] Li, Z., Yang, S., Lin, H., Huang, J., Watkins, P.A., Moser, A.B., et al., 2003.
Probiotics and antibodies to TNF inhibit inﬂammatory activity and improve
nonalcoholic fatty liver disease. Hepatology 37(2):343e350.
[57] Cheung, A.T., Wang, J., Ree, D., Kolls, J.K., Bryer-Ash, M., 2000. Tumor
necrosis factor-alpha induces hepatic insulin resistance in obese Zucker (fa/fa)
rats via interaction of leukocyte antigen-related tyrosine phosphatase with
focal adhesion kinase. Diabetes 49(5):810e819.
[58] Wieckowska, A., Papouchado, B.G., Li, Z., Lopez, R., Zein, N.N.,
Feldstein, A.E., 2008. Increased hepatic and circulating interleukin-6 levels in
human nonalcoholic steatohepatitis. American Journal of Gastroenterology
103(6):1372e1379.
[59] Klover, P.J., Zimmers, T.A., Koniaris, L.G., Mooney, R.A., 2003. Chronic
exposure to interleukin-6 causes hepatic insulin resistance in mice. Diabetes
52(11):2784e2789.
[60] Meissner, M., Lombardo, E., Havinga, R., Tietge, U.J., Kuipers, F., Groen, A.K.,
2011. Voluntary wheel running increases bile acid as well as cholesterol
excretion and decreases atherosclerosis in hypercholesterolemic mice.
Atherosclerosis 218(2):323e329.
[61] Brown, J.M., Betters, J.L., Lord, C., Ma, Y., Han, X., Yang, K., et al., 2010.
CGI-58 knockdown in mice causes hepatic steatosis but prevents diet-
induced obesity and glucose intolerance. Journal of Lipid Research
51(11):3306e3315.
[62] Guo, F., Ma, Y., Kadegowda, A.K., Betters, J.L., Xie, P., Liu, G., et al., 2013.
Deﬁciency of liver comparative gene Identiﬁcation-58 causes steatohepatitis
and ﬁbrosis in mice. Journal of Lipid Research 54(8):2109e2120.
[63] Watanabe, M., Houten, S.M., Wang, L., Moschetta, A., Mangelsdorf, D.J.,
Heyman, R.A., et al., 2004. Bile acids lower triglyceride levels via a pathway
involving FXR, SHP, and SREBP-1c. Journal of Clinical Investigation 113(10):
1408e1418.
[64] Mudaliar, S., Henry, R.R., Sanyal, A.J., Morrow, L., Marschall, H.U., Kipnes, M.,
et al., 2013. Efﬁcacy and safety of the farnesoid X receptor agonist obeticholic
acid in patients with type 2 diabetes and nonalcoholic fatty liver disease.
Gastroenterology 145(3):574e582 e571.
[65] Neuschwander-Tetri, B.A., Loomba, R., Sanyal, A.J., Lavine, J.E., Van
Natta, M.L., Abdelmalek, M.F., et al., 2015. Farnesoid X nuclear
receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis
(FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 385(9972):
956e965.
[66] Donnelly, K.L., Smith, C.I., Schwarzenberg, S.J., Jessurun, J., Boldt, M.D.,
Parks, E.J., 2005. Sources of fatty acids stored in liver and secreted via li-
poproteins in patients with nonalcoholic fatty liver disease. Journal of Clinical
Investigation 115(5):1343e1351.
[67] Oliveros, J.C., 2007. VENNY. An interactive tool for comparing lists with Venn
Diagrams.H. This is an open accessarticle under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
www.molecularmetabolism.com
